임상 한눈에 보기

• 2건의 ClinicalTrials.gov 임상 기록
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• 모집 중 1건 · 완료/종료 10건
• Phase: PHASE3 · PHASE1 · PHASE2 · PHASE1, PHASE2
• Status: TERMINATED · COMPLETED · ACTIVE_NOT_RECRUITING…
• 주요 endpoint: Overall Survival (OS) in Arms A and B · Safety Run-In Substudy: Number of Participants Experiencing Adverse Events (AEs) · Safety Run-In Substudy: Serum Concentration of Ociperlimab · Progression-free Survival (PFS) for Arm A Versus Arm B As Assessed By the Investigator · Progression-free Survival (PFS) for Safety Run-In Substudy As Assessed By the Investigator
• 등록 대상자(표본 합산): 약 2,596명
• 선택한 코호트 보고값: ORR 100%
• 핵심: The primary objectives of this study were: to assess the safety and tolerability, to determine the maximum tolerated dos…

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.